It’s never too early to think about how you can reduce your cost of goods
In the early clinical development stage of autologous cell therapy manufacturing, labor costs often dominate the overall cost of goods (COGs). However, as manufacturing scales up and out, the cost of materials — including media and reagents, consumables, and viral vectors — increases as a percentage of the total COGs.
Review the cost distribution over time for a generic autologous CAR T therapy manufacturing process using the principles of process economics — coupled with insights from scientists and R&D. Plus gain insights into how cell therapy manufacturers can combat these costs.